The Ameliorative Effect of Liraglutide (Saxenda® and Victoza®) Treatment on Overweight and Induced Diabetes Mellitus Type 2 in Male Rats.

Recent researches are increasingly focused on incretin-based therapies, which use the body's natural "incretin effect" to manage diabetes and overweight. The study's goal is to utilize the incretin-mimicking medications to leverage their efficiency. 42 male rats were allocated into 7 groups (6 rats per group); G1 (Control) received an IP injection of NS for 4 weeks. G 2 (HFD group) is categorized into 3 subgroups. The positive control group received daily injections of normal saline for 4 weeks. Victoza- and Saxenda-treated groups were administered a graduated Sc dose from 0.6 to 1.2 mg/kg daily for 4 weeks. G3-induced diabetes mellitus type 2 (IDM) is categorized into three categories: Positive control: received daily injections of NS (1 ml/kg) for 4 weeks. The Victoza- and Saxenda-treated groups received Sc injections of graduated doses from 0.6 to 1.2 mg/kg daily for 4 weeks. The results showed a significant increase in incretin hormone in the HFD and IDM Victoza groups compared to the HFD and IDM Saxenda groups, while the insulin hormone showed a considerable decrease in HFD and IDM Victoza groups compared to the same groups treated with Saxenda. HDL showed a considerable elevation in groups IDM and HFD treated with Victoza, more those treated with Saxenda. LDL levels were significantly lower in the IDM and HFD groups treated with Victoza compared to those treated with Saxenda. The study shows that these two medications work by acting as agonists at the GLP-1 receptor, which in turn increases insulin secretion and improves incretin signaling